Matthew Zorn

The mood was generally positive.

But RPH really sought to emphasize that it wants to move fast here, especially Matt Zorn, Deputy General Counsel at the Department of Health and Human Services, who was very blunt in saying that RPH only intends to support a group that will move quickly on this matter.

But it's not clear how quickly things can move.

There have been many efforts to get Ibogaine into human studies in the U.S. that have been sort of delayed.